参考文献

参考文献

［1］Li H，Zhang S，Guo J，et al.Hepatic metastasis in newly diagnosed esophageal cancer：a population-based study［J］.Front Oncol，2021，11：644860.

［2］Ajani JA，D'Amico TA，Bentrem DJ et al. Esophageal and esophagogastric junction cancers，version 2.2019，NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw，2019，17（7）：855-883.

［3］刘畅，王立峰，万百顺，等.磁共振扩散张量成像在肝癌及肝转移瘤中诊断价值［J］.安徽医药，2019，23（7）：1393-1395.

［4］Qiu G，Zhang H，Wang F et al.Patterns of metastasis and prognosis of elderly esophageal squamous cell carcinoma patients in stageⅣB：a population-based study［J］.Transl Cancer Res，2021 Nov；10（11）：4591-4600.

［5］Cunningham D，Starling N，Rao S，et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer［J］.N Engl J Med，2008，358（1）：36-46.

［6］Al-Batran SE，Hartmann JT，Probst S，et al. PhaseⅢtrial in metastatic gastroesophageal adenocarcinoma with fluorouracil，leucovorin plus either oxaliplatin or cisplatin：a study of the Arbeitsgemeinschaft Internistische Onkologie［J］.J Clin Oncol，2008，26（9）：1435-1442.

［7］Shah MA，Janjiglan YY，Stoller R，et al.Randomized multicenter phaseⅡstudy of modified docetaxel，cisplatin，and fluorouracil（DCF）versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma：a study of the US Gastric Cancer Consortium［J］.J Clin Oncol，2015，33（33）：3874-3879.

［8］Doi T，Piha-Paul SA，Jalal SI，et al.Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma［J］.J Clin Oncol，2018，36（1）：61-67.

［9］Ford HE，Marshall A，BridgeWater JA，et al.Docetaxel versus active symptom control for refractory esophagogastric adenocarcinoma（COUGAR-02）：an open-label，phase 3 randomised controlled trial［J］.Lancet Oncol，2014，15（1）：78-86.

［10］Shankaran V，Mulcahy MF，Hochster HS，et al. Docetaxel，oxaliplatin，and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction （GEJ）adenocarcinomas：Preliminary results of a phase Ⅱ study［C］.Gastrointestinal Cancers Symposium 2009，Abstract 47. Retrieved from：http：／／www. asco. org／ASCOv2／Meetings／Abstracts？& ＿＿vmview=abst detail view&confID=63&abstractID=10246.

［11］Bang YJ，Van Cutsem E，Feyereislova A，et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3，open-label，randomised controlled trial［J］.Lancet，2010，376（9742）：687-697.

［12］Kato K，Cho BC，Takahashi M，et al.Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy（ATTRACTION-3）：a multicentre，randomised，open-label，phase 3 trial［J］.Lancet Oncol，2019，20（11）：1506-1517.(https://www.daowen.com)

［13］闫东，李槐，魏文强，等.消化道肿瘤肝转移经肝动脉介入治疗的疗效评价及预后影响因素分析［J］.中华肿瘤杂志，2007，29（11）：867-870.

［14］李小平，陈震，孟志强，等.食管癌肝转移的治疗疗效观察［J］.肿瘤防治杂志，2004，11（5）：524-526.

［15］Procopio F，Marano S，Gentile D，et al. Management of liver oligometastatic esophageal cancer：overview and critical analysis of the different loco-regional treatments［J］.Cancers，2020，12（1）：20.

［16］Sara Jamel，Karina Tukanova，Sheraz Markar. Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors：A systematic review［J］.World Journal of Gastrointestinal Oncology，2019，11（9）：741-749.

［17］Iitaka D，Shiozaki A，Fujiwara H，et al.Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy：report of a case［J］.Surg Today，2013，43（5）：556-561.

［18］Lorenzen S，Schuster T，Porschen R，et al.Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus：a randomized phaseⅡstudy of the Arbeitsgemeinschaft Internistische Onkologie［J］.Ann Oncol，2009，20（10）：1667-1673.

［19］Bouche O，Raoul JL，Bonnetain F，et al. Randomized multicenter phaseⅡtrial of a biweekly regimen of fluorouracil and leucovorin（LV5FU2），LV5FU2 plus cisplatin，or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer：a Federation Francophone de Cancerologie Digestive Group Study—FFCD 9803［J］.J Clin Oncol，2004，22（21）：4319-4328.

［20］Shitara K，Doi T，Dvorkin M，et al. Trifluridine／tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer（TAGS）：a randomised，double-blind，placebo-controlled，phase 3 trial［J］.Lancet Oncol，2018，19（11）：1437-1448.

［21］Albertsson M，Johansson B，Friesland S，et al.PhaseⅡstudies on docetaxel alone every third week，or weekly in combination with gemcitabine in patients with primary locally advanced，metastatic，or recurrent esophageal cancer［J］.Med Oncol，2007，24（4）：407-412.

［22］张子凡，程志远，孟茜茜，等.食管癌肝转移预后列线图的建立———基于人群的分析［J］.中国实用内科杂志，2019，39（7）：618-623.

［23］Deng J，Chu X，Ren Z，et al.Relationship between T stage and survival in distantly metastatic esophageal cancer：a strobe-compliant study［J］.Medicine，2020，99（19）：e20064.

［24］Ghazy HF，El-Hadaad HA，Wahba HA et al.Metastatic esophageal carcinoma：prognostic factors and survival［J］.J Gastrointest Cancer，2022，53（2）：446-450.